Insider buying
~$750K101K sh @ $7.42
Traded Nov 16 · filed 1 day later
The CEO of Kura Oncology paid $750K out of pocket for Kura Oncology shares. Shares held went up 19% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 13, 2026 · Filed Nov 17, 2026
The CEO of Kura Oncology paid $754K out of pocket for Kura Oncology shares. It was the first purchase in 14 months. Shares held went up 23% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$754,462
Shares × reported transaction price
$500K–$1M
+22.7%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 14 months
Confirmed open-market purchases by the same insider in the available history
Yes
Compared with 2 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
3 days after results of Nov 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $7.77 on Nov 13, 2026, 14% above its 52-week low and 43% below its high, after a 27% drop over the previous 30 trading days
52-week range $6.80 (Nov 5, 2026) to $13.59 (Aug 25, 2026), 14% of the way up, from 250 adjusted closes. 30 trading days earlier: $10.65 on Oct 2, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any KURA insider since Sep 2025. Troy Edward Wilson's largest purchase of KURA in their filings since 2025
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
Insider buying
Traded Nov 16 · filed 1 day later
The CEO of Kura Oncology paid $750K out of pocket for Kura Oncology shares. Shares held went up 19% with this purchase.
Insider selling
Traded Nov 16 · filed the same day
A Kura Oncology officer told the SEC about a plan to sell $67K of Kura Oncology shares around Nov 16, 2026. The shares were not acquired as compensation.
Insider selling
Traded Nov 16 · filed the same day
A Kura Oncology officer told the SEC about a plan to sell $36K of Kura Oncology shares around Nov 16, 2026. The shares were not acquired as compensation.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.